AtriCure, Inc. is a medical device company providing atrial fibrillation (Afib) solutions. The Company's segment develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. The Company has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. Its Isolator Synergy System, which includes its Isolator Synergy clamps, radio frequency (RF) generator and related switchbox, provides treatment for persistent and long-standing persistent Afib concomitant. It has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Instruments & Supplies
- Sub-Industry: Health Care Equipment
- Exchange: NASDAQ
- Symbol: ATRC
- CUSIP: 04963C20
- Previous Close: $17.49
- 50 Day Moving Average: $16.799
- 200 Day Moving Average: $16.976
- 52-Week Range: $13.44 - $20.40
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -19.98
- P/E Growth: -0.800
- Market Cap: $577.86M
- Outstanding Shares: 33,239,000
- Beta: 0.54
- Net Margins: -23.78%
- Return on Equity: -19.84%
- Return on Assets: -13.01%
Companies Related to AtriCure:
- Debt-to-Equity Ratio: 0.22%
- Current Ratio: 3.19%
- Quick Ratio: 2.47%
What is AtriCure's stock symbol?
AtriCure trades on the NASDAQ under the ticker symbol "ATRC."
Where is AtriCure's stock going? Where will AtriCure's stock price be in 2017?
7 equities research analysts have issued twelve-month price targets for AtriCure's stock. Their predictions range from $17.00 to $24.00. On average, they anticipate AtriCure's share price to reach $20.57 in the next twelve months.
When will AtriCure announce their earnings?
AtriCure is scheduled to release their next quarterly earnings announcement on Tuesday, February, 21st 2017.
Who owns AtriCure stock?
AtriCure's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (14.50%), First Light Asset Management LLC (2.83%), Cortina Asset Management LLC (1.87%), State Street Corp (1.67%), Loomis Sayles & Co. L P (1.34%) and William Blair Investment Management LLC (1.32%). Company insiders that own AtriCure stock include Douglas J Seith, Elizabeth D Krell, Karen P Robards and Michael D Hooven.
Who sold AtriCure stock? Who is selling AtriCure stock?
AtriCure's stock was sold by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, FMR LLC, Royce & Associates LP, Cortina Asset Management LLC, Renaissance Technologies LLC, Allianz Asset Management AG, Kopp Investment Advisors LLC and Paradigm Asset Management Co. LLC.
Who bought AtriCure stock? Who is buying AtriCure stock?
AtriCure's stock was purchased by a variety of institutional investors in the last quarter, including Loomis Sayles & Co. L P, Axiom International Investors LLC DE, Perceptive Advisors LLC, State Street Corp, A.R.T. Advisors LLC, Two Sigma Investments LP, Tudor Investment Corp Et Al and Bayesian Capital Management LP.
How do I buy AtriCure stock?
Shares of AtriCure can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of AtriCure stock cost?
One share of AtriCure stock can currently be purchased for approximately $17.39.